Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30967863 | 1.00 | SLC6A3 (0.51) | SLC6A3KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL3682275 | 0.87 | KMT2A (0.53) | KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL4413580 | 0.83 | PTGS1 (0.60) | SLC6A3KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL9158042 | 0.81 | KMT2A (0.47) | KMT2APTGS1PTGS2MEN1CYP3A4 | |
| SCHEMBL5285160 | 0.81 | HIF1A (0.49) | SLC6A3KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL5285167 | 0.81 | HIF1A (0.49) | SLC6A3KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL9019965 | 0.81 | KMT2A (0.47) | KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL9432428 | 0.81 | KMT2A (0.47) | KMT2APTGS1PTGS2MEN1 | |
| SCHEMBL9158035 | 0.81 | KMT2A (0.47) | KMT2APTGS1PTGS2MEN1CYP3A4 | |
| SCHEMBL27740088 | 0.80 | SLC6A3 (0.46) | SLC6A3KMT2APTGS1PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-1317414-A2 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | Merck Frosst Canada & Co. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-6525025-B2 | Controlling apoptosis; cardiovascular disorders; central nervous system disorders | MERCK FROSST CANADA & CO. (CA) | 2003-02-25 | — | — | US | disclosed |
| US-20020165230-A1 | Gamma-ketoacid dipeptides as inhibitors of caspase-3 | MERCK CANADA INC. (CA) | 2002-11-07 | — | — | US | disclosed |
| WO-2002020465-A2 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | MERCK FROSST CANADA & CO. (CA) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165230-A1 | Gamma-ketoacid dipeptides as inhibitors of caspase-3 | CASP3, CASP1, CASP10 | SLC6A3 3328/4885KMT2A 3766/4885PTGS1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.